A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects.
Phase of Trial: Phase II
Latest Information Update: 24 May 2012
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 24 May 2012 Planned patient number is 126 according to European Clinical Trials Database.
- 27 Sep 2008 New trial record.